Related Experiment Video
Updated: Mar 30, 2026

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation
Published on: October 11, 2024
Profile of extended-release oxycodone/acetaminophen for acute pain
1David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA ; Ronald Reagan UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA ; UCLA Ambulatory Surgery Center, University of California Los Angeles, Los Angeles, CA, USA ; UCLA Wasserman Eye Institute, University of California Los Angeles, Los Angeles, CA, USA ; UCLA Martin Luther King Community Hospital, University of California Los Angeles, Los Angeles, CA, USA.
Abstract:
This article provides a historical and pharmacological overview of a new opioid analgesic that boasts an extended-release (ER) formulation designed to provide both immediate and prolonged analgesia for up to 12 hours in patients who are experiencing acute pain. This novel medication, ER oxycodone/acetaminophen, competes with current US Food and Drug Administration (FDA)-approved opioid formulations available on the market in that it offers two benefits concurrently: a prolonged duration of action, and multimodal analgesia through a combination of an opioid (oxycodone) with a nonopioid component. Current FDA-approved combination analgesics, such as Percocet (oxycodone/acetaminophen), are available solely in immediate-release (IR) formulations.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Modified-Release Drug Delivery Systems: Overview
Opioid Analgesics: Morphine and Other Natural Cogeners
Oral Drug Delivery Systems: Delayed-Release Systems
Oral Drug Delivery Systems: Continuous-Release Systems
